Date: 2014-12-04
Type of information: Licensing agreement
Compound: CRISPR/Cas technology
Company: Sigma-Aldrich (USA - MO) Broad Institute of MIT and Harvard (USA - MA)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On December 4, 2014, Sigma-Aldrich® Corporation announced that Sigma® Life Science, its innovative biological products and services business, has entered into a non-exclusive agreement for the use of CRISPR/Cas technology covered under patents held by the Broad Institute of MIT and Harvard . Under the agreement, Sigma-Aldrich is able to make, use and distribute the advanced gene editing tools for numerous research applications, including the generation of modified plant and animal models, custom cell line creation and for CRISPR/Cas arrayed and pooled genetic screening. This agreement enables Sigma-Aldrich to pair its lentiviral manufacturing core competency and genome editing expertise with CRISPR to create the next generation of screening tools: pre-designed or customizable individual lentiviral CRISPR clones and off-the-shelf or custom lentiviral CRISPR pools. The Company\'s first off-the-shelf offering is a collection of clones targeting the human kinome, a significant group of genes that are commonly involved in cancer and development. Sigma-Aldrich is also the exclusive distributor of the Broad Institute\'s complete Mission® shRNA and ORF libraries.
Financial terms:
Latest news:
